Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

<< Back to News

1/18/22 je Tocilizumab Subcutaneous Syringe Availability
January 18, 2022

From: "Jonathan Edwards" <jonathan.edwards@hhsys.org>
To: "Pharmacists" <grp_allpharm@hhsys.org>
Cc: "Pharmacy Buyers" <pharmbuyers@hhsys.org>
Sent: Tuesday, January 18, 2022 2:17:40 PM
Subject: Re: Tocilizumab Subcutaneous Syringe Availability
Pharmacists,

 
We are experiencing some difficulty acquiring the subcutaneous syringes of tocilizumab. These syringes are primarily utilized by Drs. Hassoun and Malavade for the treatment of cytokine release syndrome due to COVID-19. (Typical dose is 162 mg subcutaneous x 1 dose) I have discussed this issue with both physicians and they have requested that we call them in the event we do not have this product in stock for them to determine an appropriate alternative dose/route of administration.
 
Please let me know if you have any questions.
 
Thank you,
 






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved